hBD-1 vs Pemvidutide
Head-to-head comparison of hBD-1 (Human beta-defensin 1) and Pemvidutide (Pemvidutide (ALT-801), long-acting glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | hBD-1 | Pemvidutide |
|---|---|---|
| Category | Dental & Oral | Weight Management |
| Full Name | Human beta-defensin 1 | Pemvidutide (ALT-801), long-acting glucagon-like peptide-1/glucagon receptor dual agonist |
| Molecular Weight | 4490 Da | N/A |
| Half-Life | minutes to hours | Approximately 1 week |
| Amino Acids | 36 | N/A |
| Typical Dose | 1-10 µg/mL in experimental studies | Trial-dependent; once-weekly SC titration |
| Route | Topical/Intraoral | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 85 | 18 |
| Research Status | Pre-clinical | Clinical |
hBD-1 Benefits
- ✓oral innate immunity
- ✓broad antimicrobial activity
- ✓biofilm suppression
- ✓periodontal support
Pemvidutide Benefits
- ✓appetite suppression
- ✓body-weight reduction
- ✓improved liver-fat markers
- ✓better glycemic control
hBD-1 Dosing
topical peptide exposure|cell-culture or mucosal models|repeat low-dose application in research
Pemvidutide Dosing
once-weekly subcutaneous injection|gradual dose escalation|maintenance at tolerated trial dose
hBD-1 Side Effects
- ⚠protease degradation
- ⚠local irritation at high dose
- ⚠limited stability in saliva
Pemvidutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠diarrhea
Research Overview
hBD-1
hBD-1 has been studied as part of the oral mucosal defense system and is linked to host resistance against dental pathogens. Research spans periodontitis, candidiasis, and epithelial barrier biology.
Pemvidutide
Clinical studies have reported dose-dependent weight loss and favorable effects on liver fat and transaminases. It remains investigational and is not approved for obesity treatment.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.